Conflicts of interest
ovarian cancer, Breast Cancer, Cancer
OVARIAN CANCER, BREAST CANCER, CANCER
SWML reports grants from AstraZeneca during the conduct of the study; grants from Eli Lilly outside the submitted work. SMEG reports grants from AstraZeneca during the conduct of the study; institutional grants from Roche, Pfizer, Novartis, Eli Lilly, Daiichi Sankyo, AstraZeneca, and Gilead outside the submitted work; personal fees from AstraZeneca outside the submitted work. ACPS and ALTI report grants from AstraZeneca during the conduct of the study. CHS is chair of the Board of Dutch National Breast Cancer Guidelines. JRK reports grants from AstraZeneca, MSD, Eisai, Eli Lilly, and GSK outside the submitted work. AHH reports grants from the Dutch Breast Cancer Research Group during the conduct of the study and outside the submitted work. AHH has been an advisory board member for Eli Lilly. AHH received support from Pfizer to attend the ESMO 2022 Congress. SCL reports grants from AstraZeneca during the conduct of the study and outside the submitted work; grants from Eurocept Plaza, Roche, Genentech, Gilead Sciences, Tesaro, Novartis, and Agendia outside the submitted work; consulting fees from AstraZeneca; payment or honoraria from Daiichi Sankyo; other financial support for attending meetings from Daiichi Sankyo; nonfinancial support from Genentech (drug), Roche (drug), Gilead Sciences (drug), Novartis (drug), Agendia (gene expression tests), and AstraZeneca (drug). SCL has a patent (UN23A01/P-EP) pending on a method for assessing homologous recombination deficiency in ovarian cancer cells. MLS reports grants from the Dutch Cancer Society, Servier Pharma, Nutricia, Kankeronderzoekfonds Limburg, ZonMW, the Jules Coenegracht Foundation, Academische Alliantie, NWA-ORC, and TKI outside the submitted work. IJHV reports grants from AstraZeneca during the conduct of the study; grants from Pfizer and Eli Lilly outside the submitted work. VCGT-H reports grants and personal fees from AstraZeneca during the conduct of the study and outside the submitted work; grants and personal fees from Novartis and Eli Lilly; grants from Roche, Pfizer, Daiichi Sankyo, and Gilead outside the submitted work. VCGT-H has a consulting role for AstraZeneca, Eli Lilly, and Novartis. The other authors have declared no conflicts of interests.